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Abstract
Clinical trialists and statisticians are very wary of subgroup analysis, for good reasons.
Clinicians have to deal with situations in which subgroups of patients differ widely from one
another in their prognosis and response to treatment. Few trials are large enough to
demonstrate convincingly these differences in outcome, but often provide suggestive
evidence. Should we ignore this and treat all patients as the same, or should we allow
dubious statistical evidence to buttress biological plausibility in making clinical decisions?
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When meta and mega agree
When a mega-trial comes up with the same findings as a
meta-analysis, or vice versa, the evidence appears over-
whelming. This was the case with the use of intravenous
followed by oral beta-blockers in acute myocardial infarc-
tion in the International Study of Infarct Survival (ISIS)-1
study [1] and the subsequent systematic review [1]. It is
not surprising, therefore, that perhaps the most presti-
gious of cardiological organisations [2] came up with fol-
lowing the Class 1 recommendation for deciding who
should receive this therapy:
“Patients without a contraindication to beta-adreno-
ceptor blocker therapy who can be treated within
12 hours of onset of infarction, irrespective of
administration of concomitant thrombolytic therapy
or performance of primary angioplasty”.
There is no suggestion in this guideline that some patients
conforming with those criteria  might benefit or be harmed
more than others. This may well have been because the
ISIS-1 investigators were pioneers in highlighting the
potential dangers of subgroup analysis. This they did most
vividly by pointing out how the results varied with a
patient’s astrological sign.
Ignorance, inefficiency or incredulity?
In many countries, notably the UK, the contemporary use
of intravenous followed by oral beta-blockers is very low. It
was reported that the British investigators used this
therapy in only 2% of the patients in ISIS-4. Were they
ignorant or inefficient? It is unlikely that it was ignorance
because many of the hospitals participating in ISIS-4 also
participated in ISIS-1. Was it inefficiency? This is unlikely
because the use of aspirin and thrombolysis (studied inhttp://cvm.controlled-trials.com/content/1/1/028
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ISIS-2) was very high, by international standards. So it
seems probable that the physicians concerned were not
wholly convinced by ISIS-1.
How much weight should we put on biological
plausibility?
There is a tendency to believe that somehow the design-
ers of trials have been able to choose a basically homoge-
neous group of patients and, equally, that they have sound
reasons for their exclusion criteria. But this is far from the
case. Beta-blockers are known to lower blood pressure,
sometimes dangerously, in patients already hypotensive or
in acute heart failure. It was entirely appropriate, therefore,
that low blood pressure was an exclusion criterion in ISIS-
1. The investigators chose the figure of 100 mmHg, below
which one should not give the drug [1]. Why 100? There
is no reason for choosing this number except for its round-
ness. Might it not be equally appropriate to choose a
higher number? An unexpected finding in ISIS-1 was that
the main reason for the lower mortality in the treated group
was the prevention of cardiac rupture on the first day.
Hypertension is one of the factors in its genesis. As shown
in Table 1, there does seem to be a relationship between
blood pressure and outcome.
Would it be very wrong to use this information
in helping to decide whom to treat?
Although not conventionally significant, the Metoprolol in
Acute Myocardial Infarction (MIAMI) trial [3] leant support
to the ISIS-1 trial and was the most important other con-
tributor to the meta-analysis. Risk categories were prede-
fined in this study, as shown in Table 2.
Would it be right to treat the more than 50% of patients
with 0–2 risk factors with metoprolol? Yet that is what the
pundits imply we should do. On the other hand, it would be
brave to dismiss the findings in the high-risk subgroups.
A proper statistical analysis (as shown with the figures
presented in the tables) shows some, but not overwhelm-
ing, support for the arguments advanced.
Can we trust meta-analyses?
The first meta-analysis of 27536 patients [1], undertaken in
1986, was significant at the 0.02 level, and demonstrated
that intravenous followed by oral beta-blockade would save
six lives in every 1000 patients treated. The second meta-
analysis [4], of 29260 patients, undertaken in 1999, showed
no significant benefit (95% confidence interval 0.85–1.08).
Table 1
Relationship between blood pressure and clinical outcome
Systolic blood pressure Control group mortality Atenolol group mortality Odds ratio 95% confidence interval
<120 mmHg 6.8% (69/897) 7.7% (63/930) 1.147 0.804–1.635
120–159 mmHg 4.3% (171/4640) 3.7% (195/4583) 0.861 0.698–1.062
³ 160 mmHg 4.3% (73/2500) 2.9% (107/2477) 0.666 0.492–0.902
Breslow-Day test: c2 = 5.269, DF = 2, P = 0.072. Breslow-Day (low systolic blood pressure versus the other two blood pressure ranges): c2 =
3.412, DF = 1, P = 0.065. Testing for interaction of blood pressure and study, P = 0.015.
Table 2
Fifteen-day mortality in the MIAMI trial [3]
Number of risk factors (RFs) Placebo Metoprolol Odds ratio 95% confidence interval
0 0% (0/259) 0% 0/207 NA NA
1 1.3% (11/790) 1.8% (15/820) 1.32 0.602–2.891
2 5.2% (43/825) 5.6% (47/839) 1.079 0.705–1.651
3 6.3% (31/482) 5.6% (27/486) 0.856 0.503–1.457
4 9.1% (26/286) 7.0% (21/302) 0.747 0.41–1.361
³5 11.6% (30/259) 5.8% (13/223) 0.473 0.24–0.93
Breslow-Day test: c2 = 5.538, DF = 4, P = 0.236. Breslow-Day (£2 RFs versus >2 RFs): c2 = 4.016, DF = 1, P = 0.045. Testing for interaction of
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The first led authorities to recommend intravenous fol-
lowed by oral beta-blockers for all patients. By the same
logic, one should now treat no patients with this regimen.
Clearly, this is ridiculous. So do we recommend it then for
subgroups? Of course, it is desirable for the subgroups to
be defined in advance and for them to be few in number. It
is also customary to say that subgroup findings should be
hypothesis-generating, but these hypotheses are seldom
tested in adequately sized trials.
It seems to me reasonable to look for evidence of benefit
or harm in certain biologically plausible subgroups, even
though the statistical basis for this evidence is not com-
pelling. It is ludicrous and economically mad that we have
to treat 1000 patients to benefit six because our trial
methodology cannot cope. An intelligent review of sub-
groups would allow this ratio to be much more reasonable.
Conclusion
There are sound reasons for not drawing conclusions from
subgroup analysis. Certainly, it is quite wrong use a com-
puter to look for statistically significant subgroups, as was
done in the case of the astrological signs. But cardiolo-
gists have to make decisions on the basis of the very
imperfect evidence which clinical trials usually provide. Let
them use their knowledge of the biology of the condition
to interpret which subgroups are clinically relevant and
look for (albeit imperfect) statistical support.
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